Keep updated, see our News page!
THE WORD ABILITA DERIVES FROM LATIN AND MEANS “TO MAKE POSSIBLE”.
OUR COMPANY IS IN FACT FOCUSED ON DEVELOPING TECHNOLOGIES
TO ENABLE DRUG DISCOVERY EFFORTS TARGETING THE MOST CHALLENGING MULTI-SPAN MEMBRANE PROTEINS (MMPs) LIKE
G PROTEIN-COUPLED RECEPTORS (GPCRs), ION CHANNELS, AND TRANSPORTERS.
WE ARE LEVERAGING OUR PROPRIETARY ENABLED MEMBRANE PROTEIN (EMP™) TECHNOLOGY PLATFORM
TO DRIVE THE DISCOVERY OF BIOLOGICS AND SMALL MOLECULES FOR OUR PARTNERS
AND TO FUEL OUR INTERNAL PIPELINE
TRANSFORMING THE FIELD OF MULTI-SPAN MEMBRANE PROTEIN (MMP) DRUG DISCOVERY
WHAT IS OUR MISSION:
ENABLING DRUG DISCOVERY FOR INTRACTABLE MMP TARGETS, INCLUDING
G PROTEIN-COUPLED RECEPTORS, ION CHANNELS AND TRANSPORTER
THE MARKET FOR DRUGS TARGETING MMPs:
0%Of marketed drugs target MMPs
$0BAnnual global revenue for GPCRs alone
>0Medically relevant MMP targets identified in the human genome
0Therapeutic antibody approved worldwide
<0%Of medically relevant MMPs with approved drugs